Login / Signup

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.

Jerald SadoffMathieu Le GarsGeorgi ShukarevDirk HeerweghCarla TruyersAnne M de GrootJeroen StoopSarah TeteWim Van DammeIsabel Leroux-RoelsPieter-Jan BerghmansMurray KimmelPierre Van DammeJan de HoonWilliam SmithKathryn E StephensonStephen C De RosaKristen W CohenM Juliana McElrathEmmanuel CormierGert ScheperDan H BarouchJenny HendriksFrank StruyfMacaya DouoguihJohan Van HoofHanneke Schuitemaker
Published in: The New England journal of medicine (2021)
The safety and immunogenicity profiles of Ad26.COV2.S support further development of this vaccine candidate. (Funded by Johnson & Johnson and the Biomedical Advanced Research and Development Authority of the Department of Health and Human Services; COV1001 ClinicalTrials.gov number, NCT04436276.).
Keyphrases
  • sars cov
  • respiratory syndrome coronavirus
  • coronavirus disease
  • healthcare
  • endothelial cells
  • mental health
  • public health
  • primary care
  • clinical trial
  • phase iii
  • randomized controlled trial
  • phase ii
  • social media